Table 4.
Last results of Combi-D, Combi-V, CoBRIM, Columbus and Imspire 150 trial.
| Combi-D (62) | Combi-V (62) | coBRIM (66) | Columbus (67) | Imspire 150 (68) | |
|---|---|---|---|---|---|
| Treatment arm | Dabrafenib + trametinib | Dabrafenib + trametinib | Vemurafenib + Cobimetinib | Encorafenib + binimetinib | Vemurafenib + Cobimetinib + Atezolizumab |
| Control arm | Dabrafenib | Vemurafenib | Vemurafenib | Encorafenib Vemurafenib | Vemurafenib + cobimetinib |
| Last update | 5 years | 5 years | 5 years | 4 years | 2 years |
| mPFS | 11.1 | 11.1 | 12.6 | 14.9 | 15.1 |
| PFS | 17% | 20% | 14% | 26% | 43.5% |
| mOS | 25.9 | 25.9 | 22.5 | 33.6 | 28.8 |
| OS | 32% | 36% | 31% | 39% | 76.7% (2 years) |
| ORR | 68% | 68% | 68% | 64% | 66.3% |
| trAEs G3–4 | 54% | 62% | 60% | 68% | 79% |